The technical foundation guiding discussions was the international plan already in place. FAO and WOAH developed the PPR Global Control and Eradication Strategy (PPR-GCES) adopted in April 2015. The first phase of the global program (2017–2021) has been assessed, and the PPR Global Eradication Programme Blueprint (2022–2030) was published in November 2022, outlining a broader eradication approach that includes improved access to animal health services, stronger public-private-community partnerships, and intensified multi-sector collaboration.

For manufacturers and the countries relying on them, one message came through repeatedly: the blueprint’s success is tightly linked to the availability of quality-assured PPR vaccines produced under control and aligned with WOAH standards. The meeting also recognized the market and logistics realities behind that statement. With 20+ producers active across parts of Africa, the Middle East and Asia, consistency in quality control, labeling, and field usability becomes a practical constraint—not a theoretical one.

That is why the conversation leaned heavily into “how” questions. Because many PPR vaccines are heat-sensitive, participants discussed the status and validation needs of thermotolerant (TT) vaccines and the pathway for wider adoption. DIVA development (vaccines that support differentiating infected from vaccinated animals) was also part of the technical agenda, alongside a less-discussed but highly operational topic: how vaccine labeling can affect decisions made by vaccination teams in the field.

The meeting’s reported objectives ranged from tracking earlier recommendations to stress-testing whether the 2030 ambition is achievable under current conditions. Priorities included:

• aligning efforts behind the 2022–2030 blueprint,
• reviewing manufacturing capacity and future plans,
• strengthening quality control approaches (including AU-PANVAC-linked activities),
• agreeing on verification and testing methods for TT vaccines,
• and clarifying where combined (multivalent) small ruminant vaccines fit within eradication strategies.

The event also carried a regional industry angle. Following the sessions, FAO and WOAH officials and participants toured the host’s facilities, and FAO representative Dr. Felix Njeumi described the site visit positively while thanking Turkiye for its contributions to the PPR eradication program, according to the report. Separately, discussions with FAO representative Dr. Felix Poe referenced the 2011 eradication of rinderpest as proof that a coordinated global campaign can eliminate a major animal disease—raising expectations that PPR could become the next.

From a business and capacity standpoint, Dollvet representatives tied the global plan to deliverability. The company cited 400+ employees, exports to 35 countries, and a 300 million-dose production capacity, positioning industrial scale as one practical ingredient for meeting eradication timelines—especially if TT formulations and combined vaccines expand in the coming period.

The tone across stakeholder comments was consistent: PPR can be eradicated, but only if policy, science, manufacturing, and field execution stay locked together—now, not in the final years before 2030.